Endra Life Sciences reports Q1 EPS ($1.86) vs ($449.58) last year

“Obesity, type 2 diabetes and other metabolic diseases are among the most pressing health challenges today, adding in excess of $800 billion annually to U.S. healthcare costs,” said Alexander Tokman, ENDRA’s CEO. “Our TAEUS technology has the potential to shift the paradigm-providing earlier detection, broader access and enabling more personalized management of disease through accurate and inexpensive assessment of liver fat, which is a key early biomarker for various metabolic conditions and risk factors.”